| Molecular Formula | C24H19BFNO5S |
| Molar Mass | 463.29 |
| Storage Condition | 2-8℃ |
| In vitro study | HA130 completely blocks the ability of ATX to promote TEM (transendothelial migration). HA130 at 0.3 μM completely ablates the activity of ATX on TK1 uropod formation. |
| In vivo study | HA130 slows T cell migration across lymph node HEVs. HA130 decreases the "outside HEVs/inside HEVs" ratio by 3-4-fold compared to vehicle-treated animals vehicle. The s.c. administration of HA130 induces marked lymphocyte accumulation within the endothelial cell (EC) and sub-EC layers of HEVs in draining lymph nodes (LNs). |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.158 ml | 10.792 ml | 21.585 ml |
| 5 mM | 0.432 ml | 2.158 ml | 4.317 ml |
| 10 mM | 0.216 ml | 1.079 ml | 2.158 ml |
| 5 mM | 0.043 ml | 0.216 ml | 0.432 ml |
| biological activity | HA130 is a selective autotaxin (ATX) inhibitor with IC50 of 28 nM. |
| target | Autotaxin 28 nM (IC 50 ) |
| in vitro study | HA130 completely blocks the ability of ATX to promote TEM (transendothelial migration). HA130 at 0.3 μM completely ablates the activity of ATX on TK1 uropod formation. |
| in vivo study | HA130 slow T cell migration across lymph node HEVs. HA130 decreases the "outside HEVs/inside HEVs" ratio by 3-4-fold compared to vehicle-treated animals vehicle. The s.c. administration of HA130 induces marked lymphocyte accumulation with the endothelial cell (EC) and sub-EC layers of HEVs in draining Lmph nodes (LNs). |